Onconetix subsidiary amends Labcorp license; up to $300k for PRIME study of Proclarix

Onconetix, Inc.

• Proteomedix (wholly owned by Onconetix) amended license with Labcorp for a new validation study of Proclarix (PRIME Study).
• Onconetix will pay Labcorp milestone-based payments up to $300,000 total and bear all study costs.
• Mid-five-figure payments per enrolled subject batch; fixed per-subject fee if final milestone not met.
• Labcorp not required to pay royalties or milestones for use of the risk calculator in this PRIME Study.
• Labcorp must provide study results to Onconetix but Onconetix cannot use or disclose without Labcorp's consent.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.